Wockhardt sees Q2 revenue surge, driven by antibiotic innovation and biosimilar expansion
Wockhardt Limited, a leading pharmaceutical and biotechnology company, released its second-quarter financial results for the fiscal year 2024-25, showing significant growth across several critical areas. Revenue for Q2 rose by 7% year-on-year to ₹818 crore, up from ₹762 crore in the previous year, while EBITDA surged by an impressive 71%, reaching ₹139 crore compared to […]